ArticleStatistics in medicine2025
Applying the Estimands Framework to Non-Inferiority Trials: Guidance on Choice of Hypothetical Estimands for Non-Adherence and Comparison of Estimation Methods.
Article in Statistics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Compression therapies for venous leg ulcers: The VENous Ulcer Study 6 (VenUS 6), an open, multicentre, randomised clinical trial.PLoS medicine · 2026Trial
- Comparison of intention-to-treat and per-protocol results in non-inferiority trials: a methodological review protocol.BMJ open · 2025Article
- Review
- Using the ICH estimand framework to improve the interpretation of treatment effects in internet interventions.NPJ digital medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A common concern in non-inferiority (NI) trials is that non-adherence due, for example, to poor study conduct can make treatment arms artificially similar. Because intention-to-treat analyses can be anti-conservative in this situation, per-protocol analyses are sometimes recommended. However, such advice does not consider the estimands framework, nor the risk of bias from per-protocol analyses. We therefore sought to update the above guidance using the estimands framework, and compare estimators to improve on the performance of per-protocol analyses. We argue the main threat to validity of NI trials is the occurrence of "trial-specific" intercurrent events (IEs), that is, IEs which occur in a trial setting, but would not occur in practice. To guard against erroneous conclusions of non-inferiority, we suggest an estimand using a hypothetical strategy for trial-specific IEs should be employed, with handling of other non-trial-specific IEs chosen based on clinical considerations. We provide an overview of estimators that could be used to estimate a hypothetical estimand, including inverse probability weighting (IPW), and two instrumental variable approaches (one using an informative Bayesian prior on the effect of standard treatment, and one using a treatment-by-covariate interaction as an instrument). We compare them, using simulation in the setting of all-or-nothing compliance in two active treatment arms, and conclude both IPW and the instrumental variable method using a Bayesian prior are potentially useful approaches, with the choice between them depending on which assumptions are most plausible for a given trial.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.